Karyopharm Therapeutics Inc.
- Filings
- 1,036
- Raw facts
- 12,379
- Metric values
- 3,752
Q2 2026+0.6% FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026−3.1% FY25 yoy
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $146,067,000 | reported | |
| FY 2024 | 2024-12-31 | $145,237,000 | reported | |
| FY 2023 | 2023-12-31 | $146,033,000 | reported | |
| FY 2022 | 2022-12-31 | $157,074,000 | reported | |
| FY 2021 | 2021-12-31 | $209,819,000 | reported | |
| FY 2020 | 2020-12-31 | $108,085,000 | reported | |
| FY 2019 | 2019-12-31 | $40,893,000 | reported | |
| FY 2018 | 2018-12-31 | $30,336,000 | reported | |
| FY 2017 | 2017-12-31 | $1,605,000 | reported | |
| FY 2016 | 2016-12-31 | $154,000 | reported | |
| FY 2015 | 2015-12-31 | $250,000 | reported | |
| FY 2014 | 2014-12-31 | $229,000 | reported |
Segments
Products
LineFY2025ShareChange
Product$114.86M79%+1.8%
License and Other Revenue$31.21M21%−3.8%
Total$146.07M
Pharmaceutical preparations
Karyopharm Therapeutics Inc. is the 97th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
CYRXCryoport, Inc.$176.2M12.4%44.4%$968.4MPHATPhathom Pharmaceuticals, Inc.$175.1M216.9%126.3%$506.9MSNDXSyndax Pharmaceuticals Inc$172.4M627.8%165.6%$1.3BLQDALiquidia Corp$158.3M1,031.2%43.5%$5.2BHRTXHeron Therapeutics, Inc.$154.9M7.4%13.0%$63.1MMGNXMacrogenics Inc$149.5M0.3%49.9%$146.7MELTPElite Pharmaceuticals Inc$148.9M77.1%30.1%$387.8M
KPTIQKaryopharm Therapeutics Inc. (this company)$146.1M0.6%134.2%—
XNCRXencor Inc$125.6M13.7%73.2%$2.9BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR